271 related articles for article (PubMed ID: 36636157)
21. Non-insulin dependent diabetes mellitus: present therapies and new drug targets.
Das SK; Chakrabarti R
Mini Rev Med Chem; 2005 Nov; 5(11):1019-34. PubMed ID: 16307531
[TBL] [Abstract][Full Text] [Related]
22. Reversing pancreatic β-cell dedifferentiation in the treatment of type 2 diabetes.
Son J; Accili D
Exp Mol Med; 2023 Aug; 55(8):1652-1658. PubMed ID: 37524865
[TBL] [Abstract][Full Text] [Related]
23. Expert Group Consensus Opinion: Role of Anti-inflammatory Agents in the Management of Type-2 Diabetes (T2D).
Das AK; Kalra S; Tiwaskar M; Bajaj S; Seshadri K; Chowdhury S; Sahay R; Indurkar S; Unnikrishnan AG; Phadke U; Pareek A; Purkait I
J Assoc Physicians India; 2019 Dec; 67(12):65-74. PubMed ID: 31801334
[TBL] [Abstract][Full Text] [Related]
24. Klf6 protects β-cells against insulin resistance-induced dedifferentiation.
Dumayne C; Tarussio D; Sanchez-Archidona AR; Picard A; Basco D; Berney XP; Ibberson M; Thorens B
Mol Metab; 2020 May; 35():100958. PubMed ID: 32244185
[TBL] [Abstract][Full Text] [Related]
25. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
26. Pancreatic β cell dedifferentiation in diabetes and redifferentiation following insulin therapy.
Wang Z; York NW; Nichols CG; Remedi MS
Cell Metab; 2014 May; 19(5):872-82. PubMed ID: 24746806
[TBL] [Abstract][Full Text] [Related]
27. Repurposed Analog of GLP-1 Ameliorates Hyperglycemia in Type 1 Diabetic Mice Through Pancreatic Cell Reprogramming.
Villalba A; Rodriguez-Fernandez S; Perna-Barrull D; Ampudia RM; Gomez-Muñoz L; Pujol-Autonell I; Aguilera E; Coma M; Cano-Sarabia M; Vázquez F; Verdaguer J; Vives-Pi M
Front Endocrinol (Lausanne); 2020; 11():258. PubMed ID: 32477262
[TBL] [Abstract][Full Text] [Related]
28. Modulation of the pancreatic islet-stress axis as a novel potential therapeutic target in diabetes mellitus.
Ludwig B; Barthel A; Reichel A; Block NL; Ludwig S; Schally AV; Bornstein SR
Vitam Horm; 2014; 95():195-222. PubMed ID: 24559919
[TBL] [Abstract][Full Text] [Related]
29. Assessment of Risks and Benefits of Beta Cell Replacement Versus Automated Insulin Delivery Systems for Type 1 Diabetes.
Senior P; Lam A; Farnsworth K; Perkins B; Rabasa-Lhoret R
Curr Diab Rep; 2020 Aug; 20(10):52. PubMed ID: 32865637
[TBL] [Abstract][Full Text] [Related]
30. Novel peptides under development for the treatment of type 1 and type 2 diabetes mellitus.
Baron AD; Kim D; Weyer C
Curr Drug Targets Immune Endocr Metabol Disord; 2002 Apr; 2(1):63-82. PubMed ID: 12477297
[TBL] [Abstract][Full Text] [Related]
31. Managing type 2 diabetes: going beyond glycemic control.
Stolar MW; Hoogwerf BJ; Gorshow SM; Boyle PJ; Wales DO
J Manag Care Pharm; 2008 Jun; 14(5 Suppl B):s2-19. PubMed ID: 18597582
[TBL] [Abstract][Full Text] [Related]
32. Pair Feeding, but Not Insulin, Phloridzin, or Rosiglitazone Treatment, Curtails Markers of β-Cell Dedifferentiation in
Ishida E; Kim-Muller JY; Accili D
Diabetes; 2017 Aug; 66(8):2092-2101. PubMed ID: 28506962
[TBL] [Abstract][Full Text] [Related]
33. The Role of Glucagon in the Pathophysiology and Treatment of Type 2 Diabetes.
Hædersdal S; Lund A; Knop FK; Vilsbøll T
Mayo Clin Proc; 2018 Feb; 93(2):217-239. PubMed ID: 29307553
[TBL] [Abstract][Full Text] [Related]
34. Dipeptidyl peptidase IV inhibitors: the next generation of new promising therapies for the management of type 2 diabetes.
Sebokova E; Christ AD; Boehringer M; Mizrahi J
Curr Top Med Chem; 2007; 7(6):547-55. PubMed ID: 17352676
[TBL] [Abstract][Full Text] [Related]
35. The impact of diabetes and associated cardiometabolic risk factors on members: strategies for optimizing outcomes.
Hoerger TJ; Ahmann AJ
J Manag Care Pharm; 2008 Feb; 14(1 Suppl C):S2-14; quiz 15-6. PubMed ID: 18240890
[TBL] [Abstract][Full Text] [Related]
36. Pharmacological interventions that directly stimulate or modulate insulin secretion from pancreatic beta-cell: implications for the treatment of type 2 diabetes.
Farret A; Lugo-Garcia L; Galtier F; Gross R; Petit P
Fundam Clin Pharmacol; 2005 Dec; 19(6):647-56. PubMed ID: 16313276
[TBL] [Abstract][Full Text] [Related]
37. Beta-cell transplantation in type 1 diabetic patients: a work in progress to cure.
Gillard P; Keymeulen B; Mathieu C
Verh K Acad Geneeskd Belg; 2010; 72(1-2):71-98. PubMed ID: 20726441
[TBL] [Abstract][Full Text] [Related]
38. Death versus dedifferentiation: The molecular bases of beta cell mass reduction in type 2 diabetes.
Sun T; Han X
Semin Cell Dev Biol; 2020 Jul; 103():76-82. PubMed ID: 31831356
[TBL] [Abstract][Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
